Arterium Corporation presents first domestically-produced linezolid generic
Arterium Corporation has added a new presentation of Linezolidin to its product portfolio—the drug is now available as tablets No. 10. This is the first domestically-produced tableted linezolid generic.
Linezolidin is an anti-infective drug of the new class—oxazolidinone antibiotics. The product is used in the treatment of severe infections caused by susceptible strains of aerobic and anaerobic gram-positive bacteria. Linezolidin's main clinical effect is in affecting gram-positive cocci resistant to many other antibiotics. Among those are Methicillin-resistant Staphylococcus aureus (MRSA), Penicillin-resistant Streptococcus pneumoniae, and Vancomycin-resistant Enterococci.
The solid form enables application of the drug beyond sequential anti-bacterial therapy, which makes treatment more convenient. Given that the drug has almost 100% bioavailability, Linezolidin in tablet form enables efficient antibiotic treatment in outpatients and inpatients alike while requiring no skin damage.
The generic's efficiency was confirmed by the product’s biologic equivalence to the original drug1. Arterium Corporation launched sales of Linezolidin infusion solution back in 2012.
The information is provided for medical and pharmaceutical personnel only and shall be used exclusively in relevant professional activities. For full information about the medicinal product, refer to the instruction for medical use of Linezolidin tablets and Linezolidin infusion solution. This website is a specialised publication intended for medical and pharmaceutical personnel only.
1 Clinical trial involving healthy volunteers for assessment of bioequivalence of Linezolidin film-coated tablets, 600 mg, produced by Kievmedpreparat (Ukraine) and Zyvox film-coated tablets, 600 mg, produced by Pfizer Pharmaceuticals (USA).
